高盛首予兆科眼科-B(06622.HK)「买入」评级目标价20.29元_老虎社区_美港股上老虎

高盛首予兆科眼科-B(06622.HK)「买入」评级目标价20.29元

AAFN2021-06-01

高盛发表报告表示，看好兆科眼科-B 业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

风雪腊梅
·2021-06-01
[财迷] [财迷] [财迷]
回复
点赞
举报
WilllllChen
·2021-06-01
哈哈，是时候卖了
回复
点赞
举报
定位心海的锚
·2021-06-01
回发行就不错了。还20.29
回复
点赞
举报
牛星雨
·2021-06-01
千万别买，谁买谁套
回复
点赞
举报
始终微笑
·2021-06-01
呐，自己偷偷买入，然后放消息，拉升一波？
回复
点赞
举报
牛星雨
·2021-06-01
**股
回复
点赞
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2140457860?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","is_english":false,"pubTime":"2021-06-01 09:48","share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","id":"2140457860","market":"us","top_or_hot":-1,"title":"高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元","media":"AAFN","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告表示，看好<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","article_id":"2140457860","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2140457860","pubTimestamp":1622512131,"columns":[],"sourceInfo":{"source_id":"aastocks","name":"阿思达克财经"},"weMediaInfo":null,"summary":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","collect":0,"end_time":0,"defaultTopTitle":"aastocks.com","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Goldman Sachs first gave Zhaoke Ophthalmology-B (06622. HK) a \"buy\" rating target price of 20.29 yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1},"content_text":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[{"id":119846900,"gmtCreate":1622537604800,"gmtModify":1622537604800,"author":{"id":"3581155580868820","authorId":"3581155580868820","name":"风雪腊梅","avatar":"https://static.tigerbbs.com/6098bb5390cb75567a6e67bf6a793e29","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581155580868820","authorIdStr":"3581155580868820"},"htmlText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","listText":"[财迷]&nbsp;[财迷]&nbsp;[财迷]&nbsp;","text":"[财迷] [财迷] [财迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119846900","repostId":2140457860,"repostType":2,"repost":{"id":"2140457860","kind":"news","pubTimestamp":1622512131,"share":"https://www.laohu8.com/m/news/2140457860?lang=&edition=full","pubTime":"2021-06-01 09:48","market":"us","language":"zh","title":"高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元","url":"https://stock-news.laohu8.com/highlight/detail?id=2140457860","media":"AAFN","summary":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告表示，看好<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","relate_stocks":{},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140457860","content_text":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":119397133,"gmtCreate":1622517903922,"gmtModify":1622517903922,"author":{"id":"3552908658229606","authorId":"3552908658229606","name":"WilllllChen","avatar":"https://static.tigerbbs.com/ac12984bb3d16979ad2c247b4ce794d7","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3552908658229606","authorIdStr":"3552908658229606"},"htmlText":"哈哈，是时候卖了","listText":"哈哈，是时候卖了","text":"哈哈，是时候卖了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119397133","repostId":2140457860,"repostType":2,"repost":{"id":"2140457860","kind":"news","pubTimestamp":1622512131,"share":"https://www.laohu8.com/m/news/2140457860?lang=&edition=full","pubTime":"2021-06-01 09:48","market":"us","language":"zh","title":"高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元","url":"https://stock-news.laohu8.com/highlight/detail?id=2140457860","media":"AAFN","summary":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告表示，看好<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","relate_stocks":{},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140457860","content_text":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":119943210,"gmtCreate":1622515372530,"gmtModify":1622515372530,"author":{"id":"3576884508574632","authorId":"3576884508574632","name":"定位心海的锚","avatar":"https://static.tigerbbs.com/f4724c34b859ffe87fa6c33f3807576b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3576884508574632","authorIdStr":"3576884508574632"},"htmlText":"回发行就不错了。还20.29","listText":"回发行就不错了。还20.29","text":"回发行就不错了。还20.29","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119943210","repostId":2140457860,"repostType":2,"repost":{"id":"2140457860","kind":"news","pubTimestamp":1622512131,"share":"https://www.laohu8.com/m/news/2140457860?lang=&edition=full","pubTime":"2021-06-01 09:48","market":"us","language":"zh","title":"高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元","url":"https://stock-news.laohu8.com/highlight/detail?id=2140457860","media":"AAFN","summary":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告表示，看好<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","relate_stocks":{},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140457860","content_text":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":119954826,"gmtCreate":1622515120065,"gmtModify":1622515120065,"author":{"id":"3443076017674412","authorId":"3443076017674412","name":"牛星雨","avatar":"https://static.tigerbbs.com/82541fbb2d02adf6b4a6efadade2c0cb","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3443076017674412","authorIdStr":"3443076017674412"},"htmlText":"千万别买，谁买谁套","listText":"千万别买，谁买谁套","text":"千万别买，谁买谁套","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119954826","repostId":2140457860,"repostType":2,"repost":{"id":"2140457860","kind":"news","pubTimestamp":1622512131,"share":"https://www.laohu8.com/m/news/2140457860?lang=&edition=full","pubTime":"2021-06-01 09:48","market":"us","language":"zh","title":"高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元","url":"https://stock-news.laohu8.com/highlight/detail?id=2140457860","media":"AAFN","summary":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告表示，看好<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","relate_stocks":{},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140457860","content_text":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":119955973,"gmtCreate":1622515062292,"gmtModify":1622515062292,"author":{"id":"3574137596286814","authorId":"3574137596286814","name":"始终微笑","avatar":"https://static.tigerbbs.com/cef633fa8b11541ec986a66435a55295","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3574137596286814","authorIdStr":"3574137596286814"},"htmlText":"呐，自己偷偷买入，然后放消息，拉升一波？","listText":"呐，自己偷偷买入，然后放消息，拉升一波？","text":"呐，自己偷偷买入，然后放消息，拉升一波？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119955973","repostId":2140457860,"repostType":2,"repost":{"id":"2140457860","kind":"news","pubTimestamp":1622512131,"share":"https://www.laohu8.com/m/news/2140457860?lang=&edition=full","pubTime":"2021-06-01 09:48","market":"us","language":"zh","title":"高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元","url":"https://stock-news.laohu8.com/highlight/detail?id=2140457860","media":"AAFN","summary":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告表示，看好<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","relate_stocks":{},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140457860","content_text":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":119952725,"gmtCreate":1622515051967,"gmtModify":1622515051967,"author":{"id":"3443076017674412","authorId":"3443076017674412","name":"牛星雨","avatar":"https://static.tigerbbs.com/82541fbb2d02adf6b4a6efadade2c0cb","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3443076017674412","authorIdStr":"3443076017674412"},"htmlText":"**股","listText":"**股","text":"**股","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/119952725","repostId":2140457860,"repostType":2,"repost":{"id":"2140457860","kind":"news","pubTimestamp":1622512131,"share":"https://www.laohu8.com/m/news/2140457860?lang=&edition=full","pubTime":"2021-06-01 09:48","market":"us","language":"zh","title":"高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元","url":"https://stock-news.laohu8.com/highlight/detail?id=2140457860","media":"AAFN","summary":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","content":"<html><body><p><a href=\"https://laohu8.com/S/GS\">高盛</a>发表报告表示，看好<a href=\"https://laohu8.com/S/06622\">兆科眼科-B</a>  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p></body></html>","source":"aastocks","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n高盛首予兆科眼科-B(06622.HK)「买入」评级  目标价20.29元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-01 09:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0><strong>AAFN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com</p>\n\n<a href=\"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/4b6684517506a0b0f4c4c5a1c4889261","relate_stocks":{},"source_url":"http://www.aastocks.com/apps/data/iphone/news/newscontent.aspx?newsid=NOW.1102412&style=5&chgstyle=1&categoryid=stock&width=320&market_id=hk&fontary=3&platform=iPhone&language=sc&isfirstreq=1&sourceid=aafn&datatype=0","is_english":false,"share_image_url":"https://static.laohu8.com/51f6b9126f36f92bbf92982596066e5a","article_id":"2140457860","content_text":"高盛发表报告表示，看好兆科眼科-B  业务增长前景，主因内地眼科药物市场的巨大增长潜力、公司的创新和多目标管道辅以仿制药以及其作为全球眼科资产进入内地渠道的潜力等因素，首予其「买入」评级 及目标价20.29元。(sw/k)~阿思达克财经新闻网址: www.aastocks.com","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":3,"commentSize":6,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}